Matthew Griffin, award winning Futurist and Founder of the 311 Institute, a global futures think tank working between the dates of 2020 and 2070, is described as "The Adviser behind the Advisers." Regularly featured on AP, CNBC, Discovery and RT, his ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past five years as one of the world's foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive future. A rare talent Matthew sits on the Technology and Innovation Committee (TIAC) for Centrica, Europe’s largest utility company, and his recent work includes mentoring XPrize teams, building the first generation of biocomputers and re-inventing global education, and helping the world’s largest manufacturers envision, design and build the next 20 years of devices, smartphones and intelligent machines. Matthew's clients are the who’s who of industry and include Accenture, Bain & Co, BCG, BOA, Blackrock, Bentley, Credit Suisse, Dell EMC, Dentons, Deloitte, Du Pont, E&Y, HPE, Huawei, JPMorgan Chase, KPMG, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, UBS, the USAF and many others.
WHY THIS MATTERS IN BRIEF
Trying to demonstrate that new drugs don’t have any negative impacts on a patients heart is difficult, but this new technology provides research organisations with a fast, cheap way to test their new drugs without the risks.
Beating rhythmically and suspended in a jar, tiny heart-like structures made from stem cells are the latest innovation for drug testing – technology that has the potential to save pharmaceutical companies time and money. They’re developed by Canadian backed biotech firm Novoheart, which hopes to revolutionise how drugs make it to market, and they follow on from other recent biological breakthroughs from other companies who’ve so far created new Brain in a Jar, and Human on a Chip technologies, all of which will help accelerate the rate and accuracy of drug testing, and help cure disease faster.
The first thing people say when they see the tiny hearts in action company co-founder Kevin Costa says is, “Wow, it’s actually beating.… It’s actually working like a heart.”
He says the Novoheart technology is different from other stem cell derived testing methods because of the 3D structure of his company’s “Heart in a Jar.”
How Novoheart works
“We can actually measure the hollow chamber that is pumping, so we can monitor how much pressure the organ is generating, like the blood pressure,” he says, “and we can measure how fast it’s beating, like the heart rate.”
Technology like this has the potential to save pharma companies billions because the process of taking a drug through the discovery process is “lengthy and expensive,” Costa says, “it takes about a decade and a couple of billion dollars to take a drug from its initial concept to clinical trials.”
Most drugs never make it past testing, often because they are toxic to the human heart. It’s a problem that’s difficult to uncover when testing on animals and can be left undiscovered until well into the human trial phase, and Costa’s new Heart in a Jar could help change that by weeding out drugs that will cause problems for human heart cells earlier in the process.
“What we like to do is earlier in this process be able to test drugs, test compounds, in human heart muscle,” Costa says.
Novoheart says it has pharmaceutical companies interested in its technology but securities regulations prevent the company from disclosing them until the proper paperwork is filed with the securities regulator.
Making the heart valves, Novoheart biotech engineer Eugene Lee says, is a multi-step process but “it starts with taking blood cells.”
In the lab, blood cells are genetically reprogrammed into stem cells. Those are then manipulated into heart cells, which are placed by the millions into a mould.
“The cells form a kind of Jell-O like solution,” says Lee “and over time will reorganise and hug or compact near the closest thing. And it’ll take the shape of the inner mould.”
Novoheart was recently listed on the TSX Venture Exchange and has received financial backing from Canadian investors.
“I think it’s a very topical and relevant industry segment,” says Darren Devine with CDM Capital Partners, which has a stake in the company. CDM invested in Novoheart because it believes companies like it can be disrupters to the pharmaceutical industry, but in the stem cell industry, scaling up research into practical opportunities has been a problem, Devine says.
“What investors are looking at now is how do you take this science experiment and turn it into a commercial opportunity?” he says, “In order to survive companies need to prove they can get big, sustainable contracts from pharmaceutical companies that will have commercial value on a long-term basis.”
Novoheart is not alone when it comes to using stem cell derived tissue for drug testing. University of Toronto professor Milica Radisic has her own biotech startup TARA Biosystems and created something called a beating “Heart on a Chip” and says the possibilities are endless.
“You can make tissue from anybody,” Radisic says, and using a person’s own stem cells can create heart cells for patients with certain diseases, “you can use them to build tissues and test drugs.”
All of which may make it possible to test drugs on specific patients and essentially personalise drug testing.
“Initially when we started on this I must say that pharma companies were sceptical,” she says, “but things have changed. Now the question we’re getting is, ‘What is your throughput? What is your turnaround time? If we send you something how fast can you turn it over?'”
People outside the scientific community often find technology of the type that’s happening at Novoheart something of a head scratcher, but despite still being in the early stages and futuristic by nature, it’s something already getting attention from the global pharmaceutical industry.
“One large pharma company may have one, maybe two drugs approved a year,” and Radisic says this technology should change that, “there is a huge need if you think of the diseases out there that are still not cured.”